<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02491099</url>
  </required_header>
  <id_info>
    <org_study_id>1503015437</org_study_id>
    <nct_id>NCT02491099</nct_id>
  </id_info>
  <brief_title>A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma</brief_title>
  <acronym>Afatinib</acronym>
  <official_title>A Phase II Evaluation of Afatanib, an Irreversible Human Epidermal Growth Factor Receptor 2 (Her2/Neu) Tyrosine Kinase Inhibitor, in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective: To assess the activity of Afatinib in patients with persistent or&#xD;
      recurrent uterine serous carcinoma overexpressing HER2/neu with the frequency of patients who&#xD;
      survive progression-free for at least 6 months after initiating therapy. Secondary&#xD;
      Objectives: To assess objective response rate and durable disease control rate. To assess&#xD;
      overall survival. To assess the safety profile of Afatinib in uterine serous carcinoma&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exploratory/correlative objectives: To systematically evaluate HER2/neu&#xD;
      expression/amplification using standardized scoring criteria for both breast and gastric&#xD;
      cancer and correlate clinical response in uterine serous carcinoma patients with HER2/neu&#xD;
      scoring results. To correlate objective response rate, PFS and overall survival with the&#xD;
      presence/absence of phosphatidyl inositol 3-kinase catalytic subunit and F-box/WD&#xD;
      repeat-containing protein mutations by standard Sanger sequencing, and presence/absence of&#xD;
      Cyclin E2 overexpression by IHC in endometrial cancer patients overexpressing HER2/neu&#xD;
      treated with Afatinib. To study HER2/neu extracellular domain circulating levels in the&#xD;
      plasma of uterine serous carcinoma patients overexpressing HER2/neu before and during&#xD;
      Afatinib treatment to elucidate whether changes in HER2/neu extracellular domain would&#xD;
      predict response to Afatinib and to determine peripheral blood natural killer cell numbers&#xD;
      and activity in HER2/neu+ uterine serous carcinoma patients before and during Afatinib&#xD;
      treatment to assess the possible therapeutic contributions of immune mechanisms of action of&#xD;
      Afatinib.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">July 2028</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>4 Years</time_frame>
    <description>Progression free survival for at least 6 months after initiating therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety profile of Afatinib in USPC patients by CTCAE v4.0</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HER2/Neu+ Uterine Serous Carcinoma</condition>
  <arm_group>
    <arm_group_label>Afatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Afatinib 40 mgs., Q 21 Day times 4 Cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 days for subsequent cycles until progression</description>
    <arm_group_label>Afatinib</arm_group_label>
    <other_name>Irreversible Human Epidermal Growth Factor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have persistent or recurrent histologically confirmed uterine serous&#xD;
             carcinoma, harbor a tumor HER2/neu+ based upon IHC staining score of 3+ or 2+ with&#xD;
             confirmed gene amplification by FISH.&#xD;
&#xD;
          -  Have measurable disease.&#xD;
&#xD;
          -  Have at least one target lesion to be used to assess response as defined by RECIST&#xD;
             v1.1.&#xD;
&#xD;
          -  After undergoing surgery may be optimally or sub optimally debulked, with measurable&#xD;
             recurrent disease of any previous substage.&#xD;
&#xD;
          -  Diagnosis histologically confirmed by a gynecologic pathologist as containing &gt;10%&#xD;
             uterine papillary serous adenocarcinoma in the specimen.&#xD;
&#xD;
          -  Have adequate bone marrow function.&#xD;
&#xD;
          -  WBC greater than or equal to 3,000/ul, platelets greater than or equal to 75,000/ul,&#xD;
             granulocytes greater than or equal to 1500/ul., creatinine less than or equal to 2.0&#xD;
             mg/kl, bilirubin &lt; 1.5 X laboratory normal, SGOT/SGPT &lt;3 X laboratory normal.&#xD;
&#xD;
          -  Have an ECOG performance status of 0 or 1.&#xD;
&#xD;
          -  Have signed an approved consent.&#xD;
&#xD;
          -  Have recovered from effects of recent surgery, radiotherapy or chemotherapy. Should be&#xD;
             free of significant infection.&#xD;
&#xD;
          -  Patients with recurrent disease may have received multiple prior chemotherapies for&#xD;
             treatment of their uterine cancer.&#xD;
&#xD;
          -  May have received prior trastuzumab therapy alone or in combination with chemotherapy&#xD;
             with 2 week washout period required between trastuzumab treatment and first dose of&#xD;
             Afatanib.&#xD;
&#xD;
          -  Patients of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days prior to the study entry and be practicing an effective form of contraception.&#xD;
&#xD;
          -  Must be 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of other invasive malignancies, with the exception of&#xD;
             non-melanoma skin cancers are excluded if there is any evidence of other malignancy&#xD;
             being present within the last five years. Patients are also excluded if their previous&#xD;
             cancer treatment contraindicates this protocol.&#xD;
&#xD;
          -  Patients who have a significant history of cardiac disease, uncontrolled hypertension,&#xD;
             unstable angina, uncontrolled congestive heart failure, or uncontrolled arrhythmias&#xD;
             within 6 months of registration. Patients with any unstable medical issue, active&#xD;
             treatment for symptomatic pulmonary embolism, CVA, renal or hepatic insufficiency,&#xD;
             active infection/sepsis requiring IV antibiotics, known brain/leptomengial involvement&#xD;
             of the disease, active neurological disease, dementia.&#xD;
&#xD;
          -  Patients who have received prior therapy with any irreversible human epidermal growth&#xD;
             factor receptor tyrosine kinase inhibitor.&#xD;
&#xD;
          -  Patients who have an uncontrolled seizure disorder or active neurological disease.&#xD;
             Patients known to be seropositive for HIV and active hepatitis, even if liver function&#xD;
             studies are in the eligible range. Known hemorrhagic diathesis or active bleeding&#xD;
             disorder.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Santin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandro D. Santin, M.D.</last_name>
    <phone>203-737-4450</phone>
    <email>alessandro.santin@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Baker, R.N.</last_name>
    <phone>203-785-6398</phone>
    <email>lisa.baker@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Setsuko Chambers, M.D.</last_name>
      <phone>520-626-0950</phone>
      <email>schambers@uacc.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro D. Santin, M.D.</last_name>
      <phone>203-737-4450</phone>
      <email>alessandro.santin@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Baker, R.N.</last_name>
      <phone>203-785-6398</phone>
      <email>lisa.baker@yale.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Whitfield Growdon, MD</last_name>
      <phone>617-724-4800</phone>
      <email>wgrowdon@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Louisa Bauer, RN</last_name>
      <phone>617-643-5415</phone>
      <email>LJBAUER@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Whitfield Growdon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002 May;8(5):1271-9.</citation>
    <PMID>12006548</PMID>
  </results_reference>
  <results_reference>
    <citation>Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol. 2005 Jul;98(1):24-30.</citation>
    <PMID>15894362</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28.</citation>
    <PMID>23359684</PMID>
  </results_reference>
  <results_reference>
    <citation>Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2;497(7447):67-73. doi: 10.1038/nature12113. Erratum in: Nature. 2013 Aug 8;500(7461):242.</citation>
    <PMID>23636398</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. Br J Cancer. 2014 Oct 28;111(9):1750-6. doi: 10.1038/bjc.2014.519. Epub 2014 Sep 30.</citation>
    <PMID>25268372</PMID>
  </results_reference>
  <results_reference>
    <citation>Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005 Mar;192(3):813-8.</citation>
    <PMID>15746676</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 2, 2015</study_first_submitted>
  <study_first_submitted_qc>July 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2015</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

